Analysis of polymorphisms Leiden Factor V G1691A and prothrombin G20210A as risk factors for acute myocardial infarction
- 15 September 2011
- journal article
- research article
- Published by Springer Nature in Biogerontology
- Vol. 12 (5) , 485-490
Abstract
Thrombotic risk increases in elderly, therefore, the understanding of the genetic predisposition of hypercoagulability could make the difference in the prevention of venous and/or arterial thrombotic events. Laboratory evaluation of hyperfibrinogenemia, increased Factor VII levels, antiphospholipid antibodies presence and hyperhomocysteinemia are considered to have a consistent high predictivity for arterial thrombophilic diseases. Anyway, a large debate exists on the validity of testing Leiden Factor V (FV) G1691A and/or prothrombin (FII) G20210A polymorphisms in patients affected by arterial thrombotic diseases, despite of the several observations described. Here we report data strongly suggesting that at least the FII G20210A polymorphism might be considered an important risk factor for acute myocardial infarction in aged patients (55–80 years old). On the other hand, in spite of a not different genotypic and allelic distribution for the Leiden FV G1691A mutation, the presence of one or both the two polymorphisms is significantly higher among cases than in controls. In conclusion, our data suggest that FII G20210A and/or Leiden FV might be involved as risk factor for arterial disorders in about 5% of old subjects, justifying the opportunity of a genetic screening and an eventual preventive treatment, in particular in old subjects in which other and major risk factors, as hypertension and atherosclerosis, are detected.Keywords
This publication has 14 references indexed in Scilit:
- Stroke pharmacogenomicsExpert Opinion on Pharmacotherapy, 2009
- Prevalence of factor V Leiden and prothrombin G20210A mutation in a large French population selected for nonthrombotic history: geographical and age distributionBlood Coagulation & Fibrinolysis, 2009
- Pro-Inflammatory Gene Variants in Myocardial Infarction and Longevity: Implications for PharmacogenomicsCurrent Pharmaceutical Design, 2008
- Hemostasis factors and agingExperimental Gerontology, 2008
- Opposite effects of interleukin 10 common gene polymorphisms in cardiovascular diseases and in successful ageing: genetic background of male centenarians is protective against coronary heart diseaseJournal of Medical Genetics, 2004
- Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studiesAmerican Heart Journal, 2003
- Hypercoagulability as a Cause of Stroke in AdultsSouthern Medical Journal, 2003
- Coexistence of Factor V G1691A and Factor II G20210A Gene Mutations in a Thrombotic Family Is Associated with Recurrence and Early Onset of Venous ThrombosisPathophysiology of Haemostasis and Thrombosis, 2001
- Mutation in the Gene Coding for Coagulation Factor V and the Risk of Myocardial Infarction, Stroke, and Venous Thrombosis in Apparently Healthy MenNew England Journal of Medicine, 1995
- A simple salting out procedure for extracting DNA from human nucleated cellsNucleic Acids Research, 1988